Pharma News

The government has approved the signing of an agreement between India and Senegal in the field of health and medicine. The agreement includes cooperation in the fight against AIDS, integrated disease surveillance and emergency relief.

Recognizing India's "major defense partner", the United States has made the necessary changes to its export control laws that would benefit India by facilitating the transfer of technology and weapons.

The Department of Pharmaceuticals (DoP) has rejected the review application filed by FDC Ltd against price fixation of “Metformin (1000 mg), flunarizine, ramipril etc.”

A senior Commerce and industry ministry official said that Indian pharma exports in the current financial year may see a near double-digit growth and might end up on the lines with that of last year.

A study led by the University of Warwick has found a link between the removal of ovaries during hysterectomy and an increase in heart disease, cancer and premature death.

Researchers at the University of Southampton have developed a new 3D system to study human infection in the laboratory. The team, which includes infection researchers, engineers and bioinformaticians in Southampton and at University College London, have used an electrostatic encapsulation technique to make tiny 3D spheres within which human cells are infected with tuberculosis (TB) bacteria to generate conditions that more closely reflect events in patients.

UK biotech company Nemaura Pharma has announced a commitment from private investors of up to £5m for the development of a hormone Biologic using its Micro-Patch™ solid dose delivery platform. The fast-growing company has made significant progress in the reformulation of liquid vaccines administered through the skin using its solid dose delivery system. The funding is being used to accelerate Nemaura’s commercial research and development of clinical programmes to prepare the drug-device combination for market.

Arbutus Biopharma Corporation an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus (HBV) infection, announced that the Supreme Court of British Columbia granted Arbutus’ request for a pre-trial injunction against Acuitas, preventing Acuitas from sublicensing Arbutus’ lipid nanoparticle (LNP) technology until the end of October, or further order of the Court.  Under the terms of the pre-trial injunction, Acuitas is prevented from entering into any new agreements which include sublicensing of Arbutus’ LNP.

India spends about 1 percent of its gross domestic product (GDP) on public health, compared to 3 percent in China and 8.3 percent in the United States. Despite this low budget allotment, the contribution has been decreasing or kept stagnant in India since several years.

Investments and innovations in R & D activities are pushing market players to launch manufacturing projects in environmentally friendly and biodegradable packaging, which are expected to increase in the near future . In addition, the expiration of patents for various drug drugs should feed the pharmaceutical packaging market during the forecast period.